Modified Radical Mastectomy Biopsy with ER, PR, HER2/neu Panel in UAE | 1,100 AED | DHA Licensed

Executive Summary & Core Metrics

Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO Accredited Histopathology Processing.
Premium Logistics: Secure Medical Courier Solid Tissue Specimen Retrieval from the operating hospital or pathology archive; home phlebotomy is not applicable for this surgical tissue analysis.
Clinical Guidance: Telephonic Post-Test Clinical Guidance in result interpretation provided by a DHA-licensed specialist.
Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.

Test Overview & Methodology

This histopathology panel evaluates estrogen receptor (ER), progesterone receptor (PR), and HER2/neu protein expression on tissue obtained from a modified radical mastectomy. The results are critical for guiding adjuvant endocrine therapy and targeted anti-HER2 treatments, directly influencing long-term survival outcomes in breast cancer patients.

The laboratory employs standardized immunohistochemistry (IHC) protocols with automated staining platforms. Cases showing equivocal HER2 expression (2+) are reflexed to fluorescence in situ hybridization (FISH) for definitive gene amplification status, ensuring precise classification for therapeutic decision-making.

Feature	Modified Radical Mastectomy Panel (Our Service)	Standard Biopsy Marker Testing
Precision	Comprehensive ER / PR / HER2 via IHC with reflex FISH for equivocal (2+) cases, full tumor section analysis	Often limited to core biopsy with potential sampling error; HER2 reflex may not be standard
Methodology	ISO-accredited histopathology with DHA-approved protocols, automated IHC, and FISH reflex	Variable laboratory standards; manual IHC without reflex protocols
Turnaround Time	6 working days from specimen receipt	7–14 working days typical

Physician Insight & Safety Protocols

"As a specialist in diagnostic radiology, I emphasise that accurate interpretation of ER, PR, and HER2/neu status requires correlation with preoperative imaging, tumour grade, and surgical staging. These receptor markers are pivotal in guiding adjuvant therapy decisions, but they must be evaluated within the complete clinical context of the patient. A multidisciplinary tumour board review remains the gold standard for treatment planning." — Mr. Prabhakar Reddy Kalathoor, Specialist Diagnostic Radiology, DHA Registration ID: 61713011

Important Medication Advisory

Patients should continue all prescribed medications as directed by their treating physician. The results of this histopathology panel are intended to inform future treatment decisions and should not prompt any changes to current therapy without explicit consultation with the oncology team.

Safety Exclusion Criteria & Clinical Indicators

Exclusion: Active infection at the surgical site, uncorrected bleeding diathesis, or inability to provide informed consent per Federal Decree-Law No. 4 of 2016 on Medical Liability.
Red Flags: Acute-onset severe chest pain, wound dehiscence, purulent drainage, or fever exceeding 38°C post-mastectomy — immediate emergency evaluation is required.
Minors: In compliance with UAE Federal Law, testing on minors requires explicit legal guardian consent and documented clinical necessity.

Patient FAQ & Clinical Guidance

1. What do ER, PR, and HER2/neu results indicate for my treatment plan?

Answer: ER/PR positivity directs adjuvant hormonal therapy such as tamoxifen or aromatase inhibitors, significantly reducing recurrence risk in hormone-sensitive breast cancers. HER2 amplification qualifies you for targeted therapies including trastuzumab and pertuzumab, which improve survival in HER2-positive subtypes. All results are interpreted in conjunction with tumour grade, nodal status, and Ki-67 proliferation index.

2. Why is this panel performed on mastectomy tissue rather than a core needle biopsy?

Answer: The whole tumour specimen from a modified radical mastectomy provides the most comprehensive and accurate receptor assessment, particularly in heterogeneous cancers where a core biopsy may sample only a fraction of the tumour and miss areas with divergent receptor expression. This approach minimises sampling error and ensures the most reliable biomarker classification.

3. How will I receive the results and what is the typical reporting timeline?

Answer: Results are delivered within 6 working days from laboratory receipt of the FFPE tissue block. The final DHA-recognised histopathology report is accessible via the secure patient portal, and a telephonic post-test clinical guidance session is scheduled with a licensed specialist to explain the findings and their therapeutic implications.

UAE Regulatory & Data Privacy Adherence

This service complies with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All patient health data is encrypted, access-controlled, and processed exclusively within the UAE jurisdiction. The laboratory is ISO 9001:2015 certified (Cert: INT/EGQ/2509DA/3139) and operates under DHA Facility License No. 1143. Tissue specimen handling and diagnostic reporting follow the standards set by the Dubai Health Authority and the UAE Ministry of Health and Prevention.

Clinical & Logistical Metadata

Test Name	Modified Radical Mastectomy Biopsy — ER, PR, HER2/neu Panel
Price (AED)	1,100
Turnaround Time	6 Working Days
Sample Type / Matrix	Formalin-Fixed Paraffin-Embedded (FFPE) Tissue Block — Surgical Mastectomy Specimen
Methodology Used	Immunohistochemistry (IHC) with Reflex Fluorescence In Situ Hybridization (FISH) for HER2 Equivocal Cases
ICD-10-CM Code	C50.9
LOINC Code	85319-2
DHA Facility License & Laboratory Address	License No. 1143 \| Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE